CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 119 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $141 | +442.3% | 4,742 | +225.5% | 0.00% | – |
| Q2 2023 | $26 | +13.0% | 1,457 | 0.0% | 0.00% | – |
| Q1 2023 | $23 | -14.8% | 1,457 | 0.0% | 0.00% | – |
| Q4 2022 | $27 | -99.9% | 1,457 | 0.0% | 0.00% | – |
| Q3 2022 | $29,000 | +7.4% | 1,457 | 0.0% | 0.00% | – |
| Q2 2022 | $27,000 | -20.6% | 1,457 | 0.0% | 0.00% | – |
| Q1 2022 | $34,000 | -17.1% | 1,457 | 0.0% | 0.00% | – |
| Q4 2021 | $41,000 | +32.3% | 1,457 | 0.0% | 0.00% | – |
| Q3 2021 | $31,000 | +14.8% | 1,457 | 0.0% | 0.00% | – |
| Q2 2021 | $27,000 | -15.6% | 1,457 | -36.4% | 0.00% | – |
| Q4 2020 | $32,000 | -11.1% | 2,292 | 0.0% | 0.00% | – |
| Q3 2020 | $36,000 | -10.0% | 2,292 | 0.0% | 0.00% | – |
| Q2 2020 | $40,000 | +566.7% | 2,292 | +403.7% | 0.00% | – |
| Q1 2020 | $6,000 | -45.5% | 455 | 0.0% | 0.00% | – |
| Q4 2019 | $11,000 | -47.6% | 455 | -47.0% | 0.00% | – |
| Q2 2019 | $21,000 | – | 858 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |